Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Bristol Myers Squibb - Exploring new advancements in chemokine signaling in tumor biology: Focus on IL-8, CXCR1, and CXCR2

Emerging data for targeting IL-8, CXCR1, and/or CXCR2 as potential treatment options in solid tumors

Date

08 Dec 2022

Session

Bristol Myers Squibb - Exploring new advancements in chemokine signaling in tumor biology: Focus on IL-8, CXCR1, and CXCR2

Topics

Immunotherapy

Tumour Site

Presenters

Matteo Simonelli

Authors

M. Simonelli

Author affiliations

Humanitas University, Milan/IT

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

08 Dec 2022

Welcome and introductions

Presenter: Vincenzo Bronte

Session: Bristol Myers Squibb - Exploring new advancements in chemokine signaling in tumor biology: Focus on IL-8, CXCR1, and CXCR2

Resources:

Webcast

08 Dec 2022

Spotlight on I-O: Chemokine signaling and its role in tumor development and I-O resistance

Presenter: Vincenzo Bronte

Session: Bristol Myers Squibb - Exploring new advancements in chemokine signaling in tumor biology: Focus on IL-8, CXCR1, and CXCR2

Resources:

Webcast

08 Dec 2022

Caught in a NET: Reviewing IL-8, CXCR1, and CXCR2 signaling in tumor biology

Presenter: Ignacio Melero

Session: Bristol Myers Squibb - Exploring new advancements in chemokine signaling in tumor biology: Focus on IL-8, CXCR1, and CXCR2

Resources:

Webcast

08 Dec 2022

Closing remarks and audience Q&A

Presenter: Vincenzo Bronte

Session: Bristol Myers Squibb - Exploring new advancements in chemokine signaling in tumor biology: Focus on IL-8, CXCR1, and CXCR2

Resources:

Webcast